Claritas HealthTech Awarded Access by NHS to Assess Value of iRAD™ Image Enhancement in Chest Images of X-Ray, MRI, CT

LONDON and SINGAPORE, Nov. 24, 2022 (GLOBE NEWSWIRE) — Claritas HealthTech (“Claritas”), a healthcare technology company specializing in medical image enhancement and Artificial Intelligence (AI) assisted diagnostic tools, announces today that it has been awarded access to the National Covid-19 Chest Imaging Database (NCCID) curated by the AI Lab NHSE, after a rigorous and peer-reviewed assessment process to evaluate the benefits of iRADTM across modalities and conditions.

Claritas will carry out research using iRADTM, its image enhancement Software as a Medical Device (SaMD), with leading UK-based consultant Radiologists. The study will evaluate data across modalities (X-Rays, CT, and MRI) using multiple clinical, operational, and quality parameters for the benefit of patient outcomes.

Recognising the need to evaluate the performance of new technologies with data representative of the population and by clinicians delivering that care, Claritas has designed a study to evaluate the benefits of iRADTMwith data that is representative of that population,” commented, Dr. Arup Paul, Chief Clinical Strategy Officer at Claritas.

The parameters under assessment will include the optimisation of technical image quality, improvements in clinician interpretation, lesion identification and the potential of these enhanced data sets to train more accurate AI tools to further support clinicians and improve patient safety. 

Dr. Paul added, “The evaluation of iRADTM using the NCCID could deliver benefits for patients and clinicians in multiple parts of the health ecosystem from screening programmes, A&E to complex intervention planning.” 

About Claritas HealthTech Ltd.

Claritas conducts research and development in the fields of image enhancement, machine vision and artificial intelligence (“AI”) with a focus on medical image processing and AI assisted interpretation and diagnostics. Claritas aims to transform the diagnostics industry with powerful and effective software products created using image enhancement and AI technology enabling and assisting doctors and physicians to make accurate diagnosis and improve patient lives. All Claritas are fully compliant with HIPPA, PDPA and GDPR requirements.

For more information, please visit www.claritashealthtech.com

For Media Enquiries, please contact:

Devika Dutt

d.d@claritasco.com

Staff

Recent Posts

Signifier Medical Technologies’ eXciteOSA Now Covered by Medicaid in South Carolina: Reaching a Wider Patient Population with Daytime Sleep Apnea Therapy

BOSTON--(BUSINESS WIRE)--Signifier Medical Technologies Limited (“Signifier”), a leader in medical technology for sleep-disordered breathing, is…

2 hours ago

Thryv Therapeutics Inc. Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Montreal, Quebec--(Newsfile Corp. - April 4, 2024) - Thryv Therapeutics Inc., a Montreal based biotechnology…

2 hours ago

MMJ BioPharma Cultivation Sues the DEA once again – Is the DEA a Rogue Agency?

The DEA Games Continue To Delay Legitimate Marijuana Clinical Trials and ResearchWASHINGTON, DC / ACCESSWIRE…

2 hours ago

Oral Cancer Cause Joins with the V Foundation for Cancer Research

LARGO, FL / ACCESSWIRE / April 4, 2024 / Oral Cancer Cause (OCC), a non-profit…

2 hours ago

Annual Report 2023

GOTHENBURG, SWEDEN / ACCESSWIRE / April 4, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Today XVIVO Perfusion…

2 hours ago

New Life Solutions Addresses Florida Court Decision to Bring Major Changes to Abortion Laws

TAMPA, FL / ACCESSWIRE / April 4, 2024 / On April 1, 2024, the Florida…

2 hours ago